Skip to content
AnalystLens

Fortive Annual Report, Year Ended Dec 31, 2018

Filing Date
Filed February 28, 2019
Period End
December 31, 2018
Security
FTV
In the record · 2016–202610-K1010-Q328-K120

FTV filed 10 annual reports (10-K), 32 quarterly reports (10-Q) and 120 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Mar ’18Mar ’18
  2. Deal closed8-K · Oct ’20Oct ’20
  3. Leadership change8-K · Dec ’22Dec ’22
  4. Leadership change8-K · Sep ’26Sep ’26

Summary

Summary of the 10-K filed February 28, 2019. Cited figures are marked; the original filing is the authoritative source.

Fortive Corporation is a diversified industrial technology growth company operating two reportable segments, Professional Instrumentation and Industrial Technologies.

For 2018, total sales were $6.45 billiona, up from $5.76 billion in 2017, with operating profit of $1.18 billion and net earnings from continuing operations of $918.3 million. Sales from existing businesses grew 4.1%, while acquisitions contributed 7.6% and currency 0.4% to total revenue growth of 12.1%. Operating profit margin was 18.3%, down 160 basis points from 19.9% in 2017, reflecting acquisition-related transaction costs and the dilutive effect of acquired businesses.

Diluted EPS from continuing operations was $2.52b versus $2.51 in 2017. The company completed two major acquisitions in 2018: Accruent, a facilities asset management software provider for a purchase price of about $2.0 billion, and Gordian, a construction cost data provider for $778 million. It also split off its Automation & Specialty (A&S) Business to Altra Industrial Motion on October 1, 2018, generating total consideration of $2.7 billion and an after-tax gain of $1.9 billion reported within discontinued operations.

A pending acquisition of the Advanced Sterilization Products business from Ethicon, Inc. for approximately $2.7 billionc in cash is expected to close after the first quarter of 2019. Net earnings for 2018 were $2.91 billion, including discontinued operations. Balance sheet leverage increased, with long-term debt of about $3.4 billion at December 31, 2018, compared with $4.06 billion in long-term debt a year earlier.

Cash and equivalents were $1.18 billiond. Operating cash flow from continuing operations was $1.20 billion. Subsequent to year-end, the company issued $1.437 billion of 0.875% convertible senior notes due 2022 to help fund the ASP acquisition, and it declared a quarterly common dividend of $0.07 per share.

Key Highlights

  1. Total 2018 sales of $6.45 billion, up 12.1% year over year, with existing businesses growing 4.1%
  2. Operating profit margin of 18.3%, down 160 basis points from 19.9% in 2017
  3. Diluted EPS from continuing operations of $2.52 versus $2.51 in 2017; net earnings of $2.91 billion including discontinued operations
  4. Completed the split-off of the A&S Business on October 1, 2018, with a $1.9 billion after-tax gain recorded in discontinued operations
  5. Acquired Accruent (about $2.0 billion) and Gordian ($778 million net of cash acquired) in 2018, adding about $1.1 billion and $429 million of preliminary goodwill respectively
  6. Pending acquisition of Advanced Sterilization Products from Ethicon, Inc. for approximately $2.7 billion in cash, expected to close after Q1 2019
  7. Long-term debt of about $3.4 billion at year-end 2018; issued $1.437 billion of 0.875% convertible senior notes due 2022 in February 2019

Follow one dollar

Of each $1.00 of revenue in FY2018, Fortive kept $0.77.

  1. Revenue$3.80B100.0%
  2. Cost of revenue−$1.61B42.5%
  3. Gross profit$2.19B57.5%
  4. Operating costs−$1.54B40.5%
  5. Operating income$645.3M17.0%
  6. Interest, other & tax$2.27B59.7%
  7. Net income$2.91B76.7%
Computed from 10-KFY2018filed February 28, 2019Computed from this filing’s revenue, gross profit, operating income and net income · right columngrey figure: share of revenue

Where FY2018 revenue went

$3.80B
  • Cost of revenue: $1.61B, 42% of revenue
  • SG&A: $1.26B, 33% of revenue
  • Operating income: $645.3M, 17% of revenue
  • R&D: $278.1M, 7.3% of revenue

Kept 17% as operating income

Full revenue history →

Financial Statements

FY2018 against FY2017

Line itemFY2018FY2017Change
Revenue$3.80B$5.76B−34.0%
Cost of Revenue$1.61B$2.83B−43.1%
Gross Profit$2.19B$2.92B−25.2%
R&D Expenses$278.10M$369.30M−24.7%
SG&A Expenses$1.26B$1.41B−10.4%
Operating Income$645.30M$1.14B−43.5%
Interest Expense$77.20M$88.70M−13.0%
Net Income$2.91B$1.04B+179.0%
EPS (Basic)$8.33$3.01+176.7%
EPS (Diluted)$8.21$2.96+177.4%
Shares Outstanding (Basic)345.50M347.50M−0.6%
Shares Outstanding (Diluted)350.70M352.60M−0.5%

Frequently Asked Questions

  1. What drove the decline in operating profit margin in 2018?

    The filing attributes the 160 basis point decline to acquisition-related transaction costs and acquisition-related restructuring (75 basis points) and the incremental net dilutive effect of acquired businesses (120 basis points), partly offset by higher sales volumes, price increases and restructuring-related cost savings.

  2. How much did the A&S Business split-off contribute to results?

    The A&S Business is reported as discontinued operations. Total consideration was $2.7 billion, consisting of $1.3 billion from an exchange offer, $1.0 billion in cash for direct asset sales, $250.0 million in a non-cash debt-for-debt exchange and $150 million in cash dividends. The transaction produced an after-tax gain of $1.9 billion, and discontinued operations contributed $1,995.5 million to 2018 net earnings.

  3. What is the company's debt position after the 2018 acquisitions?

    Long-term debt including the current portion was $3.43 billion at December 31, 2018, down from $4.06 billion a year earlier. The company had $2.0 billion available under its revolving credit facility, with about $660 million backstopping commercial paper. Covenants require a net leverage ratio below 3.50 to 1.00, with a step-up to 4.00 to 1.00 for four quarters after a qualifying acquisition.

  4. How is the pending ASP acquisition being financed?

    The company issued $1.437 billion of 0.875% convertible senior notes due February 15, 2022 on February 22, 2019. It intends to use the net proceeds to fund part of the cash consideration for the Advanced Sterilization Products business, which is priced at approximately $2.7 billion.